Fluorescent PARP Inhibitors Applied to Intracranial Glioblastoma: Accumulation and Persistence in Vivo

Zhe Gao, Zhen Yang, Zheng Li, Kevin Burgess

Research output: Contribution to journalArticlepeer-review

Abstract

Rucaparib-containing fluorescent probes (1-3) inhibit PARP1 in cell models. One of these (1) was tested in a murine model and shown to permeate into implanted intracranial glioblastoma tumors and persist there for at least 24 h.

Original languageEnglish (US)
Pages (from-to)911-915
Number of pages5
JournalACS Medicinal Chemistry Letters
Volume13
Issue number6
DOIs
StatePublished - Jun 9 2022

Keywords

  • MHI-148
  • PARP inhibitor
  • cyanine
  • glioblastoma
  • rucaparib

ASJC Scopus subject areas

  • Biochemistry
  • Drug Discovery
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Fluorescent PARP Inhibitors Applied to Intracranial Glioblastoma: Accumulation and Persistence in Vivo'. Together they form a unique fingerprint.

Cite this